Bronchiectasis Market Size and Trends Report, Including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031


Bronchiectasis, which received the diagnosis code J47. 9 of the International Classification of Diseases, Tenth Edition (ICD-10), is defined by damage to the bronchi, causing abnormal dilation and scarring.

New York, Sept. 20, 2022 (GLOBE NEWSWIRE) — announces the release of the report “Report on Bronchiectasis Market Size and Trends, Including Epidemiology and Pipeline Analysis, Evaluation of Competitors, Unmet Needs, Clinical Trial Strategies and Forecasts, 2021-2031” –
The airways become inflamed with thick, hard-to-clean mucus, the buildup of which creates an environment for bacterial growth; uncontrolled bacterial growth leads to frequent infections. The cycle of repeated infections can in turn further damage the airways. Bronchiectasis can occur in the whole lung or in just one section of the lung. .

Bronchiectasis is still relatively poorly understood; there has been increasing emphasis on the role of underlying factors, such as the presence of comorbidities, but the development of bronchiectasis is multifactorial. and connective tissue and/or autoimmune diseases.

Although diagnosed prevalent cases of bronchiectasis are expected to increase by 21.3% over the entire 3MM, many symptomatic treatments are currently used off-label. The most frequently used drug classes are antibiotics, bronchodilators and mucolytics. Antibiotics are most often used off-label to treat patients with bronchiectasis whose lungs are colonized with bacteria as a prophylactic treatment or to treat lung infections; they can be oral, IV, or inhaled depending on the severity and type of bacteria. Mucolytics and bronchodilators are used to relieve symptoms by clearing the airways of thick mucus and widening the airways.

Bronchiectasis in 3MM Market was valued at $408.2 million in 2021. The market is expected to grow at a compound annual growth rate (CAGR) of 9.0%, reaching $965.8 million by 2031, pipeline agents adding more than $450 million in sales. In 2021, inhaled antibiotics was the market leading class with $265.6 million in sales and is expected to remain the leader with $314.5 million in sales in 2031. The main driver of this growth will be the planned launch of new pipeline agents such as Fasenra and brensocatib which forecast 2031 sales of $171.2 million and $271.6 million, respectively.

– The bronchiectasis market will show significant growth between 2021 and 2031, driven by the entry of several pipeline agents. These new entrants will transform the bronchiectasis market by providing more treatment options for patients with frequent exacerbations.
– In 2021, inhaled antibiotics were the market leading class with $265.6 million in sales, and are expected to remain the leader with $314.5 million in sales in 2031
– KOLs expressed enthusiasm for late-stage agents Fasenra, an interleukin (IL)-5 inhibitor, and brensocatib, a dipeptidyl peptidase 1 (DPP-1) inhibitor, due to their novel mechanisms action and innovation they would bring to market; if approved, they would both be top of their respective classes.
– The greatest unmet needs in bronchiectasis are the lack of marketed drugs and the need for improved diagnosis. Despite having three pipeline agents in late-stage development, a significant unmet need is expected to remain representing an opportunity for developers in the bronchiectasis market

Answers to key questions
– What were the main bronchiectasis treatments available in 2021?
– When will the late-stage pipeline products be launched and how will they affect drug sales and the overall bronchiectasis market in 3MM?
– What unmet needs will remain unmet during the forecast period and what opportunities remain for pharmaceutical companies?

– Overview of bronchiectasis, including epidemiology, symptoms, diagnosis and management of the disease.
– Bronchiectasis therapeutics market annualized revenue, treatment cost per patient and treatment utilization patterns; forecast from 2021 to 2031.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and the implications of these factors for the bronchiectasis therapeutics market.
– Pipeline analysis comprising comprehensive data assessing emerging trends and mechanisms of action under development for the treatment of bronchiectasis. The most promising candidates in Phase III and Phase IIb development are profiled.
– Analysis of current and future competition in the global Bronchiectasis Therapeutics market. In-depth review of key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to buy
The report will allow you to –
– Develop and design your licensing and out-licensing strategies through a review of pipeline products and technologies, and identifying companies with the strongest pipeline.
– Develop business strategies by understanding the trends shaping and driving the global Bronchiectasis Therapeutics market.
– To generate revenue by understanding the key trends, innovative products and technologies, market segments and companies that are likely to impact the global Bronchiectasis Therapeutics market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
– Organize your sales and marketing efforts by identifying the categories and market segments that present the maximum opportunities for consolidations, investments and strategic partnerships.
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.


CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

Source link

Comments are closed.